Researchers at Shanghai Institute of Materia Medica of the Chinese Academy of Sciences and at Tongji University have disclosed glutaminyl-peptide cyclotransferase-like protein (QPCTL; IsoQC) and glutaminyl-peptide cyclotransferase (QPCT; QC) inhibitors reported to be useful for the treatment of cancer, obesity, aging, immunological disorders and neurological disorders.
JAK2 inhibitors (JAK2i) are the standard treatment for myelofibrosis (MF), offering symptom relief and reducing spleen size. However, all FDA-approved JAK2i are type I inhibitors, which fail to eliminate the mutant MPN clone, leading many patients to treatment discontinuation.
Ipsen SA has signed an exclusive licensing agreement with Simcere Zaiming Pharmaceutical Co. Ltd. for global rights outside of Greater China for SIM-0613, an LRRC15-targeting antibody-drug conjugate developed by Simcere Zaiming for solid tumors. The program is expected to enter phase I development in the second half of next year.
Mondego Bio Lda has selected protein tyrosine phosphatase non-receptor type 2 (PTPN2) inhibitor ZE00-0388 as its lead clinical candidate. The company is targeting initiation of a first-in-human phase I study in the first half of next year.
Small molecules that induce iron-dependent oxidative cell death known as ferroptosis can be effective against tumors that are resistant to other therapies. Several such molecules, such as RSL3, work by inhibiting glutathione peroxidase 4 (GPX4), an enzyme that mitigates oxidative stress and on which metastatic cancer cells depend in order to undergo the epithelial-mesenchymal transition.
Ehrlich Biotechnology Co. Ltd. has described antibody-drug conjugates comprising an antibody targeting EGFR (HER1; erbB1) covalently linked to a camptothecin derivative through a linker reported to be useful for the treatment of cancer.
Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has disclosed RAC-α serine/threonine-protein kinase (AKT1; PKB α) (Glu17Lys mutant) inhibitors reported to be useful for the treatment of leukemia.
Amira Therapeutics SL has announced new preclinical findings for its lead compound AMI-463, which is being developed primarily for rhabdomyosarcoma, the most common soft tissue sarcoma in children. AMI-463 is a first-in-class inhibitor that blocks the cell adhesion molecule (CAM)-related down-regulated by oncogenes (CDON).
Cartography Biosciences Inc. has received IND approval from the FDA for CBI-1214, a T-cell engager being developed for the treatment of colorectal cancer.
RSS
